Capmatinib
Who holds supplier records for Capmatinib? No organisation holds a current US Type II DMF or EU CEP for Capmatinib in the registers PharmaTek covers.
Most records are filed under another form of this substance: Capmatinib Hydrochloride (2 current sources). A DMF or CEP is listed under the form it names.
Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records
Cite as: PharmaTek, “Capmatinib: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/capmatinib
Reading the evidence
- No current DMF or CEP on record
The covered registers hold no supplier record for this substance. This is not evidence that no one makes it: suppliers may file under another name, sell outside the US and EU, or use an ASMF.
- US product patents listed
The latest patent listed in the FDA Orange Book for an approved product containing Capmatinib expires 22 Jul 2035. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.
Current records (0)
Organisations holding an active US FDA Type II Drug Master File or a CEP for Capmatinib. Country is the organisation's recorded country, not necessarily the manufacturing site.
Not found in the covered registers (FDA DMF list, EDQM). This is not evidence that no supplier exists.
The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.
US product patents and exclusivity
The FDA Orange Book lists patents and exclusivities for specific approved products (2 listed products contain Capmatinib). The latest listed patent expires 22 Jul 2035. The latest listed exclusivity runs to 6 May 2027. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.
Other forms of this substance
A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:
Overview
Capmatinib is a tyrosine kinase inhibitor targeting the MET receptor, indicated for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations. It works by blocking the MET signaling pathways, which are active in various cancers.
Chemical identity
- IUPAC name
- 2-fluoro-N-methyl-4-[7-(quinolin-6-ylmethyl)imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide
- Canonical SMILES
- CNC(=O)C1=C(C=C(C=C1)C2=NN3C(=CN=C3N=C2)CC4=CC5=C(C=C4)N=CC=C5)F
- InChIKey
- LIOLIMKSCNQPLV-UHFFFAOYSA-N
- Synonyms
- Tabrecta API, inc-280, inc280, incb-28060, incb-28060 free base, nvp-inc280, nvp-inc280-nx
Therapeutic areas
Record history
PharmaTek records which organisations hold a current DMF or CEP for Capmatinib every week, starting 23 Oct 2026. Additions and lapses will appear here from the next weekly release.
Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week
What these records establish
- An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
- A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
- Historical records show a past filing, not current supply.
- Company GMP certificates are matched to the organisation, not to the site making this substance.
- A substance missing from these registers is not evidence that no supplier exists.
Frequently asked questions
Does the FDA Orange Book list patents for products containing Capmatinib?
Yes. The latest patent listed for an approved US product containing Capmatinib expires 22 Jul 2035, across 2 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.
How do I qualify a Capmatinib supplier?
Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.
Do you supply Capmatinib?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.